

Press Release

Tuesday, December 16, 2014

BSE: 532531

NSE: STAR

Strides Arcolab receives US FDA approval for Calcitriol Softgel Capsules

Product to be launched shortly

Bangalore, December 16, 2014: Strides Arcolab Limited (Strides) today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Calcitriol Softgel Capsules, 0.25mcg and 0.5mcg**.

According to IMS data, the US market for generic Calcitriol Softgel Capsules is approximately USD 50 Million, with only three players having approval for both the strengths of Calcitriol.

The product will be manufactured at the Company's Oral dosage facility at Bangalore and marketed by Strides in the US Market

About Calcitriol

Calcitriol is a Vitamin D capsule, used in patients with kidney disease who can't make enough of the active form of Vitamin D. This medication is also used to prevent and treat certain types of calcium/phosphorus/parathyroid problems that can happen with long-term kidney dialysis or hypoparathyroidism. Calcitriol is usually used along with specific diet recommendations and sometimes other medications.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products. The Company has 8 manufacturing facilities presence in more than 75 countries in developed and emerging markets. Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

Strides Arcolab Limited	PR Consultancy - Weber Shandwick
Mohan Kumar, CEO - Pharma +91 80 6784 0748	Kaveri Mandanna: +91 90089 59697 KMandanna@webershandwick.com
Vikesh Kumar +91 80 6784 0827 Kannan N +91 98450 54745	Mahesh Nair: +91 98803 76648 MNair@webershandwick.com

